PAS
PCRX icon

Point72 Asia (Singapore)’s Pacira BioSciences PCRX Stock Holding History

Point72 Asia (Singapore)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,450
Closed -$103K – 1124
2024
Q4 		$103K Buy
+5,450
New +$95.7K 0.03% 365
2024
Q2 		– Sell
-3,987
Closed -$116K – 1391
2024
Q1 		$116K Buy
+3,987
New +$122K 0.03% 597

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Point72 Asia (Singapore)'s PCRX Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 5,450 shares — an estimated $103K sold.

Point72 Asia (Singapore) first reported a position in PCRX in Q1 2024 and held it in 2 quarters. The position peaked at $116K in Q1 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 5,450 Pacira BioSciences shares in Q1 2025, an estimated $103K.
  • Point72 Asia (Singapore) first reported a position in Pacira BioSciences in Q1 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Pacira BioSciences position peaked at $116K in Q1 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.